TRVITrevi Therapeutics, Inc.

HealthcareUSD
$17.93

The financials

Trevi Therapeutics, Inc. by the numbers

Trevi Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$21M−$14Mn/a
Net income−$18M−$12Mn/a
Diluted EPS−$0.11−$0.09n/a

Biotechnology

Ranks #15 of 145 by Smart Score

Compare peers
CLDX+0.92%
Celldex Therapeutics, Inc.
KLRA-3.3%
Kailera Therapeutics, Inc.
IRON-0.30%
Disc Medicine, Inc.
MBX+4.1%
MBX Biosciences, Inc.
TARS-4.1%
Tarsus Pharmaceuticals, Inc.
SLBT+12%
SL Science Holding Limited